Results 51 to 60 of about 71,934 (217)

Neonatal dilated cardiomyopathy

Revista Portuguesa de Cardiologia, 2017
Cardiomyopathies are rare diseases of the heart muscle, of multiple causes, that manifest with various structural and functional phenotypes but are invariably associated with cardiac dysfunction.
Paulo Soares, Gustavo Rocha, Susana Pissarra, Henrique Soares, Filipa Flôr-de-Lima, Sandra Costa, Cláudia Moura, Sofia Dória, Hercília Guimarães   +8 more
doaj   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Pseudo dilated cardiomyopathy: Dilated cardiomyopathy-like changes due to a combination of stuck mechanical mitral valve and coronary microvascular dysfunction-An autopsy case. [PDF]

Clin Case Rep, 2023
Namura S, Matsuzoe H, Inaba M, Nishio R, Matsumoto D, Takaishi H.   +5 more
europepmc   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Bioinformatics identifies key genes and potential drugs for energy metabolism disorders in heart failure with dilated cardiomyopathy

Frontiers in Pharmacology
Background: Dysfunction in myocardial energy metabolism plays a vital role in the pathological process of Dilated Cardiomyopathy (DCM). However, the precise mechanisms remain unclear.
Haixia Wang, Peifeng Cai, Xiaohan Yu, Shiqi Li, Wei Zhu, Wei Zhu, Yuntao Liu, Yuntao Liu, Dawei Wang, Dawei Wang   +9 more
doaj   +1 more source

A contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation

ESC Heart Failure, Volume 12, Issue 2, Page 1166-1175, April 2025.
A contemporary simple risk score for prediction of severe AKI after HT. Abstract Background The aim of this study was to develop a simple risk score to estimate severe acute kidney injury (AKI) risk based on a large contemporary heart transplantation (HT) cohort.
Shuangshuang Zhu, Weihua Qiao, Yixuan Wang, Ying Zhou, Yin Xu, Shijie Wang, Tian Xia, Guohua Wang, Si Chen, Jiawei Shi, Nianguo Dong   +10 more
wiley   +1 more source

Left ventricular diastolic dysfunction worsens prognosis in patients with heart failure due to dilated cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1183-1193, April 2025.
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk, Ewa Dziewięcka, Sylwia Wiśniowska‐Śmiałek, Agnieszka Stępień, Katarzyna Graczyk, Agata Leśniak‐Sobelga, Marta Hlawaty, Jakub Woźniak, Maryia Savitskaya, Katarzyna Holcman, Magdalena Kostkiewicz, Piotr Podolec, Paweł Rubiś   +12 more
wiley   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of the EXCELLENT Trial Investigators   +17 more
wiley   +1 more source

EFFECT OF BETA-BLOCKERS AND STUDY OF AGGREGATiVE ACTIVITY OF THROMBOCYTES IN PATiENTS WITH DILATED CARDIOMYOPATHY

Acta Biomedica Scientifica, 2012
The aim. was to study peculiarities of ischemic and idiopathic dilated cardiomyopathy and. aggregative activity of thrombocytes and. also the response to the therapy by beta-blockers (Atenolol and Bisoprolol). Material and.
P. N. Isakhanova, Yu. N. Ziyaev
doaj  

Dilated cardiomyopathy due to novel LMNA mutation: a case report

Frontiers in Cardiovascular Medicine
A case of a 44-year-old man presenting with a family history of LMNA mutation and cardiac symptoms (dizziness, weakness, palpitations, and shortness of breath) congruent with dilated cardiomyopathy.
Riddhi Patel, Raj Patel, Ekta Patel, Mehul Patel   +3 more
doaj   +1 more source